International Biotechnology Trust’s BioCryst Pharmaceuticals BCRX Stock Holding History

International Biotechnology Trust’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-57,000	Closed	-$475K	–	66
2023 Q1	$475K	Hold	57,000	–	–	0.13%	59
2022 Q4	$654K	Hold	57,000	–	–	0.2%	57
2022 Q3	$718K	Buy	57,000 +56,398	+9,368%	+$726K	0.23%	56
2022 Q2	$57K	Sell	602 -56,398	-99%	-$582K	0.59%	39
2022 Q1	$19.3M	Buy	+57,000	New	+$914K	4.35%	6

Other funds holding BCRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.56% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

International Biotechnology Trust's BCRX Position: Q2 2023 in Review

International Biotechnology Trust sold out of BioCryst Pharmaceuticals (BCRX) in Q2 2023, closing a stake of 57,000 shares — an estimated $475K sold.

International Biotechnology Trust first reported a position in BCRX in Q1 2022 and held it in 5 quarters. The position peaked at $19.3M in Q1 2022. 235 funds tracked by Wall St. Rank hold BCRX as of Q2 2023.

International Biotechnology Trust reported no remaining BioCryst Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
International Biotechnology Trust sold 57,000 BioCryst Pharmaceuticals shares in Q2 2023, an estimated $475K.
International Biotechnology Trust first reported a position in BioCryst Pharmaceuticals in Q1 2022 and held it in 5 quarters.
International Biotechnology Trust's BioCryst Pharmaceuticals position peaked at $19.3M in Q1 2022.
235 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2023.

Based on International Biotechnology Trust's 13F filing for Q2 2023, filed 8 Aug 2023.